CASP3 and prostate carcinoma: In prostate cancer cells (LNCaP) compared with a normal prostate cell line (PC‐3), the gamma‐tocotrienol therapeutic mechanism was identified to upregulate apoptosis by activating c‐JUN, caspases 3 and 9, and the Ras/Raf/ERK pathway.169